Modulate Bio is pioneering a new generation of neuro-medicines through the development of novel GABA A positive allosteric modulators aimed at treating various neurological disorders, including Essential Tremor, epilepsy, and anxiety. The company's innovative platform allows for precise control over the activation of the GABA A receptor, which enhances therapeutic efficacy while minimizing side effects commonly associated with existing treatments. By focusing on validated biological targets and employing strong translational assays, Modulate Bio aims to bridge the gap between preclinical research and clinical application, addressing significant unmet needs in the treatment of central nervous system (CNS) disorders.

The team at Modulate Bio, comprised of experienced professionals in neuromedicine and drug development, has already established proof of concept in animal models and is on the verge of identifying a development candidate for Essential Tremor. Their approach not only targets high-need indications but also has the potential for broad application across various CNS conditions, including anxiety and depression. With a strong foundation in scientific research and a commitment to advancing patient care, Modulate Bio is positioned to make significant contributions to the field of neuropharmacology.

United States

"We are developing next-generation therapies to treat neurological disorders. 

Patients first: Our lead small molecule is a GABA-A modulator targeting Essential Tremor (ET), fine-tuned to restore healthy receptor function while avoiding excessive receptor activation. This allows for preserved efficacy and reduce side-effects. We achieved preclinical in vivo proof-of-concept, and are now identifying a lead clinical candidate. Following, we plan to develop therapies for anxiety and epilepsy. "

Modulate Bio

Company Details